Tissue Regenix is a pioneering, international medical technology company, leading the development of regenerative products to make replacement body parts using biological (human & animal) materials.
The company’s patented decellularisation (‘dCELL®’) technology removes DNA and other cellular material from tissue leaving an acellular scaffold which is not rejected by the patient’s body. The potential applications of dCELL® are diverse and address critical clinical needs such as wound care, heart valve replacement and knee repair.
The dCELL® process involves the creation of biological scaffolds which are essentially inert, and therefore classified as Medical Devices or transplant materials. This means that our products are typically subject to faster and less costly regulatory approval procedures than, for example, pharmaceutical products.
The market for human therapeutic products employing tissue engineering is one of the most rapidly growing sectors within the medical products sector.
Tissue Regenix is developing and commercialising a range of medical devices and treatments based on our patented dCELL® process. We have established operations in the US and UK to target multi-billion dollar global healthcare markets.
Tissue Regenix is currently focusing on three core product areas, through its TRX Wound Care, TRX Cardiac and TRX Orthopaedic division, working with our research partners (including the University of Leeds, Brazil’s Pontifical University of Parana, and NHSBT) to commercialise the intellectual property rights they generate.
Greg Bila was appointed President of Tissue Regenix USA when the subsidiary company was established in November 2012. Greg leads the commercialisation strategy for the dCELL® technology platform in the USA.
Greg joined Tissue Regenix from Kinetic Concepts Inc. (‘KCI’), where he held a number of sales and marketing roles. He has over 20 years’ experience in the pharmaceutical and medical devices industry, including working for Takeda Pharmaceuticals America, Daiichi Sankyo and AstraZeneca.
Peter Hamer was appointed as Business Development Manager of the Tissue Regenix Orthopaedics division in early 2013. Peter is responsible for leading the development of sales and marketing activity of the Group’s Orthopaedics product range.
Peter has over 20 years of sales and marketing experience, 12 years of which have been in senior management roles, and he has held roles at companies including Biomet and Allergan.
Peter previously worked at Corin Group, leading all export sales territories through third party distributor networks, as well as for the Corin Group UK subsidiary sales and marketing business and customer services department.
Tony Hewitt joined Tissue Regenix in June 2014 and was subsequently appointed UK Operations Director in January 2015. Tony has considerable operational experience, having worked for over 20 years within the medical device and pharmaceutical sectors. Prior to working at Tissue Regenix he held a variety of technical, manufacturing and operational management positions with Sanofi Aventis, Smith & Nephew and Covidien.
A founder of Tissue Regenix, Eileen is also Professor of Medical Immunology, Director of the Institute of Medical and Biological Engineering, a member of the Cardiovascular Research Institute at Leeds (CRISTAL) and the Skin Research Centre. Her particular area of expertise is in tissue engineering, biocompatibility, immunology and the biological activity of materials.
Mike Izon was joined as Head of QA/RA and Clinical at Tissue Regenix in November 2014. With a background in pharmaceutical products and medical devices, Mike has worked over the last 10 years as a consultant, trainer and assessor for the certification and registration of medical devices. Having worked extensively with early stage medical device development companies, Mike has also worked with household names such as Procter & Gamble, Bausch & Lomb and Carl Zeiss Medical to achieve worldwide market clearance for a range of products and technologies.
Antony Odell joined Tissue Regenix in January 2008 and was subsequently appointed Managing Director of Tissue Regenix in October 2008. He has extensive commercial experience in the medical technology sector. As well as working as Co-Director of Xeno Medical, a medical technology consultancy, he was CEO for a UK NHS cardiovascular device spin-out, Tayside Flow Technologies Ltd. Antony has a strong corporate sector background having worked for J&J Medical for almost 10 years in European business development roles for Drug Delivery & Vascular Access and as General Manager (UK) for Fresenius (Critical Care & Diagnostics).
Andrea Rausch was appointed as Business Development Manager in the Tissue Regenix Cardiac team in August 2012. Andrea joined Tissue Regenix from Sorin Group, a global medical device company and a leader in the development of medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.
For two years, she was Global Marketing Manager at Sorin for the Perceval Programme, a new treatment option for aortic valve disease, having been Business Line Leader and Strategic Sales and Marketing Manager of the Heart Valves team in Germany for five years before this.
John Samuel joined Tissue Regenix as Executive Chairman in March 2008. John qualified as a Chartered Accountant with Price Waterhouse and has held a number of senior finance positions in industry, including as Financial Director of Whessoe plc and Ellis & Everard plc. He was formerly the CEO of the Molnlycke Health Care Group, a global provider of single use surgical and wound care products to the healthcare sector. Until January 2010 he was a Partner with Apax Partners LLP.
dCELL® human dermis patches may allow a better chance of healing for chronic wounds (including ulcers and burns) and potentially faster healing for acute wounds (including surgical incisions and traumatic injuries).
dCELL® heart valves replace the patient’s own damaged valves, and may provide a biological scaffold for population by patient's own cells.
dCELL® decellularises porcine meniscus for implanting into the patient’s knees as a matrix to attract stem-cells and allow natural healing of damaged joints.
dCELL® vascular patches can be used in vascular surgery to provide effective closure with evidence of integration with patient’s own vessel.
Sign up to our mailing list to keep up with the latest news and developments from Tissue Regenix.
View alerts sign-up page
© Tissue Regenix Group plc 2017
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.